ArticleJournal of the American Heart Association2022
Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Differential Biventricular Strain Recovery With Selective Fibrosis Biomarker Regression After Sleeve Gastrectomy: A Prospective CMR Feature-Tracking Study.Obesity surgery · 2026Article
- Association of childhood-to-adulthood body size trajectories with cardiovascular risk and all cause mortality.International journal of obesity (2005) · 2026Article
- Dynamic remodeling of the pancreas immune landscape in obesity.Nature communications · 2026Article
- The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment.Journal of the American College of Cardiology · 2025Review
- Galectin-3 Reflects Systemic Atherosclerosis in Patients with Coronary Artery Disease.Medicina (Kaunas, Lithuania) · 2025Observational
- Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence.European journal of medical research · 2025Review
- Galectin-3 in Cardiovascular Health: A Narrative Review Based on Life's Essential 8 and Life's Simple 7 Frameworks.Current issues in molecular biology · 2025Review
- Diagnosing Heart Failure with Preserved Ejection Fraction in Obese Patients.Journal of clinical medicine · 2025Review
- Obesity-Related Phenotype of Heart Failure With Preserved Ejection Fraction: A Comprehensive Review.Cureus · 2025Review
- Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population.Current heart failure reports · 2024Review
- Galectin 3 rs4644 gene polymorphism is associated with metabolic traits in Serbian adolescent population.Journal of medical biochemistry · 2024Article
- Exploring the Mechanistic Link Between Obesity and Heart Failure.Current diabetes reports · 2023Review
- The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature.International journal of molecular sciences · 2023Review
- Effectiveness of Spironolactone in Terms of Galectin-3 Levels in Patients with Heart Failure with a Reduced Ejection Fraction in the Vietnamese Population.Healthcare (Basel, Switzerland) · 2023Article
- Variants TaggingGenes · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
Abstract
Background Laboratory data suggest obesity is linked to myocardial inflammation and fibrosis, but clinical data are limited. We aimed to examine the association of obesity with galectin-3, a biomarker of cardiac inflammation and fibrosis, and the related implications for heart failure (HF) risk. Methods and Results We evaluated 8687 participants (mean age 63 years; 21% Black) at ARIC (Atherosclerosis Risk in Communities) Visit 4 (1996-1998) who were free of heart disease. We used adjusted logistic regression to estimate the association of body mass index (BMI) categories with elevated galectin-3 (≥75th sex-specific percentile) overall and across demographic subgroups, with tests for interaction. We used Cox proportional hazards models to assess the combined associations of galectin-3 and BMI with incident HF (through December 31, 2019). Higher BMI was associated with higher odds of elevated galectin-3 (odds ratio [OR], 2.32; 95% CI, 1.88-2.86) for severe obesity ([BMI ≥35 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.